ASH 2021 | ReVenG: Venetoclax and obinutuzumab in CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, describes the ongoing Phase II ReVenG trial (NCT04895436) of venetoclax and obinutuzumab in pretreated patients with chronic lymphocytic leukemia (CLL). Patients will have been previously treated with venetoclax and obinutuzumab but have relapsed. Additional venetoclax and obinutuzumab will be administered for a year in patients with at least two years of remission, and venetoclax will be administered for two years in patients with one to two years of remission. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
So, I’ve also presented, at this ASH Meeting, the ReVenG trials in progress poster. This is a study for patients who have received Venetoclax plus Obinutuzumab as an initial therapy, and later go on to relapse at least one year later. And the study involves re-treatment of these patients with the same regimen Venetoclax plus Obinutuzumab. If they had at least a two-year remission, they would go on to receive one year of Venetoclax plus Obinutuzumab again...
So, I’ve also presented, at this ASH Meeting, the ReVenG trials in progress poster. This is a study for patients who have received Venetoclax plus Obinutuzumab as an initial therapy, and later go on to relapse at least one year later. And the study involves re-treatment of these patients with the same regimen Venetoclax plus Obinutuzumab. If they had at least a two-year remission, they would go on to receive one year of Venetoclax plus Obinutuzumab again. If they had only a one to two-year remission from initial therapy, they could get a two-year, or longer, course of Venetoclax. And the primary endpoint of the study is overall response rate. So we hope this will be able to read out fairly quickly to help us to understand whether we can use Venetoclax plus Obinutuzumab as a time-limited regimen for a second time.
This study is a collaboration between ourselves at Dana-Farber, the German CLL Study Group, and AbbVie. So it’s an international study. And I hope we’ll approve quickly to help answer this important question for our field.
Read more...
Disclosures
Matthew Davids, MD, has received consultancy fees from AbbVie, BeiGene, Adaptive Biotechnologies, Janssen, Takeda, Merck, Eli Lilly and Company, and Celgene; consultancy fees and research funding from Pharmacyclics, Astra-Zeneca, BMS, TG Therapeutics, Genentech, MEI Pharma, Novartis, Verastem, Ascentage Pharma, and Surface Oncology.
